Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.
Diamyd Medical fast-tracks type 1 diabetes Phase 3 trial after FDA alignment on earlier efficacy readout
Find out how Diamyd Medical is accelerating its type 1 diabetes Phase 3 trial after FDA alignment—what this means for approval, adoption, and risk.